



At ACADIA, our mission is to bring innovative medicines to patients who have disorders of the central nervous system (CNS). We are driven to improve lives by never losing sight of our patients and their families. For the Rett syndrome community, we look forward to initiating a Phase 3 study to further explore the potential benefits of trofinetide for girls with Rett syndrome. This study will begin in the second half of 2019 following completion of manufacturing scale-up activities and will evaluate treatment with trofinetide compared to placebo in approximately 180 girls with Rett syndrome.

Earlier this summer, we signed an exclusive licensing agreement for trofinetide with Neuren Pharmaceuticals and immediately assumed responsibility for the necessary research to seek FDA approval of trofinetide for Rett syndrome. Since then, we have spent many hours collaborating with Neuren and Rettsyndrome.org (RSO) to learn more about their research and development experience with trofinetide. We have also met with multiple families and other patient advocacy organizations to learn more about life with Rett syndrome.

This past October, ACADIA and Neuren held an all-day meeting with RSO staff and several investigators who participated in the Phase 2 study to gain feedback on our Phase 3 study plans. Some of the most important learnings were about practical considerations and how we can make participation in the Phase 3 study easier for patients and their families. For example, it's important we consider the length and frequency of study visits to make them manageable for those who enroll in the study. We have simplified the dosing of trofinetide, and for this study the drug will be more concentrated so there will be less volume to take at each dose.

We are intensely working to manufacture the clinical drug supply required for the Phase 3 study and to ensure that production meets strict quality guidelines. We will then also be prepared to manufacture the drug on a much larger scale should trofinetide be approved by the FDA for the treatment of Rett syndrome.

We plan to invite all of the clinical study centers who participated in the last Phase 2 trofinetide study to be part of the Phase 3 study and we may also add other study sites in the United States. We will let you know more specifics about timing, study site locations, and more details about the study as our plans crystallize.

The ACADIA Rett Team